0000000000899688

AUTHOR

M Johnson

showing 13 related works from this author

Safety and efficacy of non-steroidal anti-inflammatory drugs to reduce ileus after colorectal surgery

2019

Ileus is common after elective colorectal surgery, and is associated with increased adverse events and prolonged hospital stay. The aim was to assess the role of non-steroidal anti-inflammatory drugs (NSAIDs) for reducing ileus after surgery.A prospective multicentre cohort study was delivered by an international, student- and trainee-led collaborative group. Adult patients undergoing elective colorectal resection between January and April 2018 were included. The primary outcome was time to gastrointestinal recovery, measured using a composite measure of bowel function and tolerance to oral intake. The impact of NSAIDs was explored using Cox regression analyses, including the results of a c…

Malerenal failureTime Factorsmedicine.medical_treatmentAdult; Aged; Anti-Inflammatory Agents Non-Steroidal; Elective Surgical Procedures; Female; Humans; Ileus; Kaplan-Meier Estimate; Male; Middle Aged; Patient Safety; Postoperative Care; Postoperative Complications; Proportional Hazards Models; Prospective Studies; Recovery of Function; Time Factors; Treatment Outcome; Colectomy; ProctectomyAnti-Inflammatory Agentscolorectal surgery; ileus; non-steroidal anti-inflammatory drugs; NSAIDSKaplan-Meier Estimate030230 surgeryTumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14]0302 clinical medicinePostoperative ComplicationsProspective StudiesProspective cohort studyColectomyColorectalColectomyRISKProctectomyHazard ratioAnti-Inflammatory Agents Non-SteroidalAcute kidney injuryMiddle AgedColorectal surgeryNSAIDTreatment OutcomeElective Surgical Procedures030220 oncology & carcinogenesisFemalePatient SafetyNon-SteroidalCohort studyAdultcolorectal Surgery ileus non-steroidal anti-inflammatory drugsmedicine.medical_specialtyIleusNon‐steroidal anti‐inflammatory drugs. NSAIDs. Postoperative ileus. Colorectal surgery.ACUTE KIDNEY INJURYanti-inflammatory agents03 medical and health sciencesIleusInternal medicinemedicineHumansAdverse effectAgedProportional Hazards Modelsnon-steroidal anti-inflammatory drugs - ileus - colorectal surgeryPostoperative Carebusiness.industryRecovery of Functionmedicine.diseaseSettore MED/18 - Chirurgia Generalecolorectal cancer.Surgerycolorectal surgerybusiness
researchProduct

Search for First-Generation Scalar and Vector Leptoquarks

2001

We describe a search for the pair production of first-generation scalar and vector leptoquarks in the eejj and enujj channels by the D0 Collaboration. The data are from the 1992--1996 ppbar run at sqrt{s} = 1.8 TeV at the Fermilab Tevatron collider. We find no evidence for leptoquark production; in addition, no kinematically interesting events are observed using relaxed selection criteria. The results from the eejj and enujj channels are combined with those from a previous D0 analysis of the nunujj channel to obtain 95% confidence level (C.L.) upper limits on the leptoquark pair-production cross section as a function of mass and of beta, the branching fraction to a charged lepton. These lim…

QuarkPhysicsNuclear and High Energy PhysicsParticle physics010308 nuclear & particles physicsBranching fractionScalar (mathematics)High Energy Physics::PhenomenologyTevatronFOS: Physical sciencesHERA01 natural sciencesHigh Energy Physics - ExperimentNuclear physicsHigh Energy Physics - Experiment (hep-ex)Pair production0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]LeptoquarkHigh Energy Physics::Experiment010306 general physicsLepton
researchProduct

Safety of hospital discharge before return of bowel function after elective colorectal surgery

2020

Ileus is common after colorectal surgery and is associated with an increased risk of postoperative complications. Identifying features of normal bowel recovery and the appropriateness for hospital discharge is challenging. This study explored the safety of hospital discharge before the return of bowel function.A prospective, multicentre cohort study was undertaken across an international collaborative network. Adult patients undergoing elective colorectal resection between January and April 2018 were included. The main outcome of interest was readmission to hospital within 30 days of surgery. The impact of discharge timing according to the return of bowel function was explored using multiva…

operativeMalepostoperative dischargePostoperative Complications0302 clinical medicineColostomyCRITERIAProspective StudiesBowel functionColectomyIMAGINEstomaintestinesProctectomyIleostomydigestive oral and skin physiologypatient dischargecolorectal surgery hospital discharge bowel functionRECOVERYMiddle Agedadult; colostomy; elective surgical procedures; female; follow-up studies; humans; ileostomy; ileus; male; middle aged; multivariate analysis; patient discharge; patient readmission; patient safety; postoperative complications; prospective studies; recovery of function; colectomy; proctectomyPatient DischargeColorectal surgeryileus - - discharge - bowel function - elective - colorectal surgeryElective Surgical Procedures030220 oncology & carcinogenesisFemale030211 gastroenterology & hepatologyPatient SafetyCohort studysafetyAdultmedicine.medical_specialtyIleusPatient Readmissiondefecation03 medical and health sciencesIleuspostoperative complicationsmedicineHospital dischargeHumanscolorectal surgery; postoperative discharge; IMAGINE; stomacolorectal resectionColorectal resectiondefecation postoperative complications colorectal surgery intestines patient discharge patient readmission safety surgical procedures operative colorectal resection ileusbusiness.industryRecovery of FunctionOdds ratiomedicine.diseasedigestive system diseasessurgical proceduresSurgeryMultivariate AnalysisDefecationcolorectal surgerySurgerybusinessFollow-Up Studies
researchProduct

Higgs boson studies at the Tevatron

2013

We combine searches by the CDF and D0 Collaborations for the standard model Higgs boson with mass in the range 90-200 GeV/c2 produced in the gluon-gluon fusion, WH, ZH, tt̄H, and vector boson fusion processes, and decaying in the H→bb̄, H→W+W-, H→ZZ, H→τ+τ-, and H→γγ modes. The data correspond to integrated luminosities of up to 10 fb-1 and were collected at the Fermilab Tevatron in pp̄ collisions at √s=1.96 TeV. The searches are also interpreted in the context of fermiophobic and fourth generation models. We observe a significant excess of events in the mass range between 115 and 140 GeV/c2. The local significance corresponds to 3.0 standard deviations at mH=125 GeV/c2, consistent with the…

FERMILAB TEVATRON COLLIDERNuclear and High Energy PhysicsParticle physicsproton antiproton collisions; FERMILAB TEVATRON COLLIDER; Standard Model Higgs boson; BROKEN SYMMETRIESSTANDARD MODELP(P)OVER-BAR COLLISIONSTevatronFOS: Physical sciencesContext (language use)ATLAS DETECTORddc:500.2Standard Model Higgs boson7. Clean energy01 natural sciencesStandard ModelVector bosonHigh Energy Physics - ExperimentNuclear physicsHigh Energy Physics - Experiment (hep-ex)SEARCH0103 physical sciencesBibliography[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]BROKEN SYMMETRIESFermilab010306 general physicsPhysicsHIGGS BOSONB-JET IDENTIFICATIONLarge Hadron ColliderPP COLLISIONS010308 nuclear & particles physics4. EducationHigh Energy Physics::PhenomenologyROOT-S=1.96 TEVPARTON DISTRIBUTIONSExperimental High Energy PhysicsHiggs bosonproton antiproton collisionsComputingMethodologies_DOCUMENTANDTEXTPROCESSINGSYMMETRIESCDFB-JET IDENTIFICATION; STANDARD MODEL; ATLAS DETECTOR; PP COLLISIONS; P(P)OVER-BAR COLLISIONS; PARTON DISTRIBUTIONS; ROOT-S=1.96 TEV; SEARCH; LHC; SYMMETRIESHigh Energy Physics::ExperimentLHC
researchProduct

Direct search for charged Higgs bosons in decays of top quarks

2001

We present a search for charged Higgs bosons in decays of pair-produced top quarks in pbar p collisions at sqrt(s) = 1.8 TeV using 62.2 pb^-1 of data recorded by the D0 detector at the Fermilab Tevatron collider. No evidence is found for signal, and we exclude at 95% confidence most regions of the (M higgs, tan beta) parameter space where the decay t->H b has a branching fraction greater than 0.36 and B(H -> tau nu) is large.

QuarkParticle physicsPhysics::Instrumentation and DetectorsHigh Energy Physics::LatticeTevatronFOS: Physical sciencesGeneral Physics and AstronomyParameter space01 natural sciencesHigh Energy Physics - Experimentlaw.inventionNuclear physicsHigh Energy Physics - Experiment (hep-ex)law0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Fermilab010306 general physicsColliderBosonPhysics010308 nuclear & particles physicsBranching fractionHigh Energy Physics::PhenomenologyExperimental High Energy PhysicsComputingMethodologies_DOCUMENTANDTEXTPROCESSINGHiggs bosonPhysics::Accelerator PhysicsHigh Energy Physics::Experiment
researchProduct

Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study

2011

Background and objectives: Guidelines indicate a plasma HIV-1 RNA load of 500-1000 copies/mL as the minimal threshold for antiretroviral drug resistance testing. Resistance testing at lower viral load levels may be useful to guide timely treatment switches, although data on the clinical utility of this remain limited. We report here the influence of viral load levels on the probability of detecting drug resistance mutations (DRMs) and other mutations by routine genotypic testing in a large multicentre European cohort, with a focus on tests performed at a viral load <1000 copies/mL. Methods: A total of 16511 HIV-1 reverse transcriptase and protease sequences from 11492 treatment-experienced …

MaleDrug ResistanceHIV InfectionsDrug resistanceCohort Studies0302 clinical medicineGenotypeHIV InfectionPharmacology (medical)030212 general & internal medicineViral0303 health sciencesProteolytic enzymesGenotypic testing; HIV; Viral load; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Europe; Female; Genotype; HIV Infections; HIV-1; Humans; Male; RNA Viral; Viral Proteins; Drug Resistance Viral; Mutation Missense; Viral Load; Pharmacology; Pharmacology (medical); Infectious DiseasesViral LoadGenotypic testing3. Good healthEuropeInfectious DiseasesCohortRNA ViralFemaleViral loadCohort studyHumanMicrobiology (medical)AdultGenotypeAnti-HIV AgentsMutation MissenseBiologySettore MED/17 - MALATTIE INFETTIVE03 medical and health sciencesViral ProteinsSDG 3 - Good Health and Well-beingDrug Resistance ViralHumansViral ProteinPharmacology030306 microbiologyHIVAnti-HIV AgentVirologyReverse transcriptaseCD4 Lymphocyte CountRegimenHIV; genotypic testing; viral loadGenotypic testing; HIV; Viral load; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Resistance Viral; Europe; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Mutation Missense; RNA Viral; Viral Load; Viral ProteinsImmunologyMutationHIV-1RNAMissenseCohort Studie
researchProduct

Search for new particles in the two-jet decay channel with the DØ detector

2016

We present the results of a search for the production of new particles decaying into two jets in pp collisions at √s = 1.8 TeV, using the DØ 1992-1995 data set corresponding to 109 pb-1. We exclude at the 95% confidence level the production of excited quarks (q*) with masses below 775 GeV/c2, the most restrictive limit to date. We also exclude standard-model-like W′ (Z′) bosons with masses between 300 and 800 GeV/c2 (400 and 640 GeV/c2). A. W√ boson with mass &lt;786 GeV/c2 has been excluded by previous measurements, and our lower limit is therefore the most stringent to date. © 2004 The American Physical Society.

QuarkPhysicsNuclear and High Energy PhysicsParticle physics010308 nuclear & particles physicsAstrophysics::High Energy Astrophysical PhenomenaDetectorJet (particle physics)01 natural sciencesLower limitlaw.inventionNuclear physicslawExcited state0103 physical sciencesHigh Energy Physics::ExperimentLimit (mathematics)Nuclear Experiment010306 general physicsColliderBosonPhysical Review D
researchProduct

Search for new physics using QUAERO: A general interface to D0 Event data

2001

We describe Quaero, a method that i) enables the automatic optimization of searches for physics beyond the standard model, and ii) provides a mechanism for making high energy collider data generally available. We apply Quaero to searches for standard model WW, ZZ, and ttbar production, and to searches for these objects produced through a new heavy resonance. Through this interface, we make three data sets collected by the D0 experiment at sqrt(s)=1.8 TeV publicly available.

PhysicsHigh energyInformation retrieval010308 nuclear & particles physicsInterface (Java)Physics beyond the Standard ModelGeneral Physics and AstronomyFOS: Physical sciencesQ codeD0 experiment01 natural scienceslaw.inventionHigh Energy Physics - ExperimentHigh Energy Physics - Experiment (hep-ex)Event datalawExperimental High Energy Physics0103 physical sciencesComputingMethodologies_DOCUMENTANDTEXTPROCESSING[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]High Energy Physics::ExperimentStatistical physics010306 general physicsColliderStandard model (cryptography)Physical Review Letters
researchProduct

Cigarette smoke increases TLR4 and modifies LPS mediated responses in airway epithelial cells.

2008

Airway epithelium is emerging as a regulator of innate immune responses to a variety of insults including cigarette smoke. The main goal of this study was to explore the effects of cigarette smoke extracts (CSE) on Tolllike receptor (TLR) expression and activation in a human bronchial epithelial cell line (16-HBE). The CSE increased the expression of TLR4 and the lipopolysaccharide (LPS) binding, the nuclear factor-jB (NF-jB) activation, the release of interleukin-8 (IL-8) and the chemotactic activity toward neutrophils. It did not induce TLR2 expression or extracellular signal-regulated signal kinase 1/2 (ERK1/2) activation. The LPS increased the expression of TLR4 and induced both NF-jB a…

cigarette smokeSettore MED/10 - Malattie Dell'Apparato Respiratorioairway epithelial cellToll-like receptors
researchProduct

Direct measurement of the W boson decay width

2002

Based on 85 pb-1 data of p (p) over bar collisions at roots=1.8 TeV collected using the D empty set detector at Fermilab during the 1994-1995 run of the Tevatron, we present a direct measurement of the total decay width of the W boson Gamma(W). The width is determined from the transverse mass spectrum in the W-->e+nu(e) decay channel and found to be Gamma(W)=2.23(-0.14)(+0.15)(stat)+/-0.10(syst) GeV, consistent with the expectation from the standard model.

PhysicsNuclear and High Energy PhysicsParticle physics010308 nuclear & particles physicsTevatron01 natural sciences7. Clean energylaw.inventionStandard ModelNuclear physicslaw0103 physical sciencesTransverse momentumExperimental High Energy PhysicsTransverse massHigh Energy Physics::ExperimentFermilabNuclear Experiment010306 general physicsColliderBar (unit)
researchProduct

Quasi-model-independent search for new physics at large transverse momentum

2001

We apply a quasi-model-independent strategy ("Sleuth") to search for new high p_T physics in approximately 100 pb^-1 of ppbar collisions at sqrt(s) = 1.8 TeV collected by the DZero experiment during 1992-1996 at the Fermilab Tevatron. Over thirty-two e mu X, W+jets-like, Z+jets-like, and 3(lepton/photon)X exclusive final states are systematically analyzed for hints of physics beyond the standard model. Simultaneous sensitivity to a variety of models predicting new phenomena at the electroweak scale is demonstrated by testing the method on a particular signature in each set of final states. No evidence of new high p_T physics is observed in the course of this search, and we find that 89% of …

PhysicsNuclear and High Energy PhysicsParticle physics010308 nuclear & particles physicsPhysics beyond the Standard ModelTevatronFOS: Physical sciencesEmpty setState (functional analysis)01 natural sciencesHigh Energy Physics - Experiment3. Good healthStandard ModelSet (abstract data type)Nuclear physicsHigh Energy Physics - Experiment (hep-ex)Experimental High Energy Physics0103 physical sciencesComputingMethodologies_DOCUMENTANDTEXTPROCESSING[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]High Energy Physics::ExperimentFermilabElectroweak scale010306 general physics
researchProduct

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

2017

Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…

MaleSTATIN THERAPYAnticholesteremic Agents/adverse effectsAntibodieVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Injections Subcutaneous/adverse effects030204 cardiovascular system & hematologyBococizumablaw.inventionPCSK90302 clinical medicineRandomized controlled triallawRisk FactorsGENETIC-VARIANTSCardiovascular DiseaseMonoclonalAnticholesteremic Agent030212 general & internal medicineMyocardial infarctionTreatment FailureHumanizedProprotein Convertase 9/antagonists & inhibitorsMedicine(all)Antibodies; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections Subcutaneous; Lipids; Male; Middle Aged; Proprotein Convertase 9; Risk Factors; Treatment Failure; Medicine (all)Anticholesteremic AgentsMedicine (all)PCSK9 InhibitorsAntibodies; antibodies monoclonal humanized; anticholesteremic agents; cardiovascular diseases; cholesterol LDL; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (all)Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]General MedicineLipidMiddle AgedLipids3. Good healthLDL/bloodMulticenter StudyCholesterolTRIALSCholesterol LDL/bloodCardiovascular DiseasesAntibodies Monoclonal Humanized/adverse effectsanticholesteremic agentsRandomized Controlled Trialsubcutaneouslipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Cardiovascular Diseases/prevention & controlREDUCING LIPIDSHumanmedicine.medical_specialtyanimal structuresInjections SubcutaneousHypercholesterolemiaHypercholesterolemia/drug therapyPlaceboAntibodies Monoclonal HumanizedInjections SubcutaneouAntibodiesLDLInjectionsFollow-Up StudielipidsEVENTS03 medical and health sciencesantibodies monoclonal humanizedDouble-Blind MethodInternal medicinemedicineJournal ArticleHumansComparative StudyMETAANALYSISAlirocumabbusiness.industryUnstable anginaLipids/bloodPCSK9Risk FactorfungiAntibodies/bloodCholesterol LDLta3121medicine.diseaseSurgerycardiovascular diseasesEvolocumabREDUCTIONHumanized/adverse effectsSubcutaneous/adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

Combination of measurements of the top-quark pair production cross section from the Tevatron Collider

2014

We combine six measurements of the inclusive top-quark pair (tt̄) production cross section (σtt̄) from data collected with the CDF and D0 detectors at the Fermilab Tevatron with proton-antiproton collisions at s=1.96TeV. The data correspond to integrated luminosities of up to 8.8fb-1. We obtain a value of σtt̄=7.60±0.41pb for a top-quark mass of mt=172.5GeV. The contributions to the uncertainty are 0.20 pb from statistical sources, 0.29 pb from systematic sources, and 0.21 pb from the uncertainty on the integrated luminosity. The result is in good agreement with the standard model expectation of 7.35-0.33+0.28pb at next-to-next-to-leading order and next-to-next-to leading logarithms in pert…

Top quarkP(P)OVER-BAR COLLISIONSTevatron7. Clean energylaw.inventionPhysics Particles & FieldsHigh Energy Physics - ExperimentHigh Energy Physics - Experiment (hep-ex)law[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]HADRON COLLIDERSFERMILABFermilabNuclear ExperimentQuantum chromodynamicsPhysicsLarge Hadron ColliderPhysicsP(P)OVER-BAR COLLISIONS; ROOT-S=1.96 TEV; PARTON DISTRIBUTIONS; HADRON COLLIDERS; LEADING ORDER; T(T)OVER-BAR; DETECTOR; LHC; QCD; FERMILABPerturbative QCD3. Good healthROOT-S=1.96 TEVPhysical SciencesComputingMethodologies_DOCUMENTANDTEXTPROCESSINGLHCT(T)OVER-BARParticle physicsNuclear and High Energy PhysicsFOS: Physical sciencesAstrophysics::Cosmology and Extragalactic AstrophysicsAstronomy & AstrophysicsMASSNuclear physicsSEARCHColliderParticle PhysicsDETECTORAstrophysics::Galaxy AstrophysicsScience & Technologyhep-exLEADING ORDERHigh Energy Physics::PhenomenologyTop quarkQCDP(P)OVER-BAR COLLISIONS; T(T)OVER-BAR; DETECTOR; SEARCH; MASSPair productionPARTON DISTRIBUTIONSExperimental High Energy PhysicsCollider PhysicsCDFHigh Energy Physics::ExperimentParticle Physics; Collider Physics; Top quark
researchProduct